



# Study of Factor VIII Inhibitor and F8 Gene Mutations in Persons with Hemophilia A from Benin

Tatiana Baglo <sup>a,b\*</sup>, Alban Zohoun <sup>a,b</sup>, Bienvenu Houssou <sup>a</sup>,  
Romaric Massi <sup>a</sup>, Charlotte Orou Guiwa <sup>a</sup>, Ludovic Anani <sup>b</sup>,  
Dorothee Kindé Gazard <sup>a,b</sup> and Awa Omar Touré Fall <sup>c,d</sup>

<sup>a</sup> Hematology Laboratory, National Teaching Hospital Hubert Koutoukou Maga of Cotonou, Benin.

<sup>b</sup> Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

<sup>c</sup> Hematology Laboratory of the Aristide le Dantec Hospital, Dakar, Senegal.

<sup>d</sup> Faculty of Medicine, Pharmacy and Odontostomatology- Cheikh Anta Diop University of Dakar, Senegal.

## Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

## Article Information

DOI: 10.9734/IBRR/2024/v15i1333

## Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/113484>

Original Research Article

Received: 18/12/2023

Accepted: 25/02/2024

Published: 01/03/2024

## ABSTRACT

**Aim:** determine the prevalence of a FVIII inhibitors and identify the genetic mutations associated with their development in beninese personne with hemophilia (PwH) A.

**Study Design:** this is cross-sectional descriptive study conducted from June 2022 to May 2023 in hemophilia treatment centers in Benin.

**Methodology:** Inhibitor screening was carried out systematically in all PwHs A receiving FVIII infusion through determination of the circulating anticoagulant index and the Nijmegen-Bethesda assay. The molecular study strategy used for the F8 gene associated with hemophilia A is

\*Corresponding author: E-mail: [tatianabag@yahoo.fr](mailto:tatianabag@yahoo.fr);

dependent on the severity of the hemophilia. Other data were collected either from patients' responses to the questionnaire or by studying their medical records and the center's hemophilia registry.

**Results:** Of the 97 PwHs A followed up, 57 had been treated with FVIII infusion. Of these, 21 had developed inhibitors, representing a frequency of 36.8% of treated PwHs A and 43.75% of severe PwHs. None of the moderate or mild PwHs A had developed anti-FVIII antibodies. PwHs A with inhibitors had a median age of 11 years, ranging from 1 to 66 years. The Nijmegen-Bethesda test revealed 11 high responders and 10 low responders. Mutation analysis of the F8 gene revealed seven cases of intron 22 inversion, seven cases of nonsense mutations, three cases of deletion and one case of missense mutation. Mutations weren't identified in three patients because their DNA did not amplify on long-distance PCR. In terms of therapy, immune tolerance induction wasn't achieved in any of the 21 patients, but they are treated with emicizumab and bypass depending on the context.

**Conclusion:** Although a cross-sectional study with a limited sample size, this study provides valuable information on beninese PwHs A with inhibitors. The frequency of inhibitors is high in treated PwHs A, and almost all patients who have developed inhibitors have high-risk genetic mutations.

*Keywords: Hemophilia A; inhibitors; Nijmegen-Bethesda test; F8 gene variants; genetics.*

## 1. INTRODUCTION

A most important complication of replacement therapy in the management of hemophilia A is the development of anti FVIII inhibitors. These alloantibodies, against infused FVIII mostly neutralize its pro-coagulant activity, markedly compromising the efficacy of antihemophilic treatment [1] and increases the morbidity and mortality associated with hemophilia A [2]. Typically, inhibitor onset occurs within the initial 10 to 50 days of treatment with infused FVIII [3,4]. After 50 exposure days (EDs), the probability of inhibitor development diminishes substantially. Among, the prevalence of factor VIII inhibitors in these previously treated persons with hemophilia A (PwHs A) varies geographically, averaging approximately 30% in severe cases and 5% in moderate to mild cases [5]. The risk of formation of an inhibitor is influenced by the genetic and environmental factors. The type of genetic mutation in the FVIII gene has a major influence on inhibitor formation. This study aims to ascertain the prevalence of anti-factor VIII inhibitors and delineate the genetic mutations associated with their development in beninese persons with hemophilia A.

## 2. PATIENTS AND METHODS

This cross-sectional descriptive study was conducted from June 2022 to May 2023. It aimed to include all patients with hemophilia A exposed to FVIII products from various manufacturers and of various purities at hemophilia treatment

centers (HTC) in Benin. Screening of inhibitors was systematically conducted among all PwHs either receiving infused FVIII as part of this study, upon suspicion of therapeutic inefficacy or following management of a severe hemorrhagic event. Data were collected through a questionnaire administered to patients with hemophilia A aged 18 years and above, or to their parents if they were minors, These data were supplemented by a study of medical records and the hemophilia registry of the center. Collected variables included the severity of hemophilia A, medical history, age at diagnosis of anti-factor VIII inhibitors, age at diagnosis of hemophilia, bleeding complications of hemophilia, type of treatment received, number of EDs and the type of genetic mutation of PwHs.

Screening of factor VIII inhibitors was established using the mixing test activated partial thromboplastin time (APTT) followed by confirmation via Nijmegen-Bethesda assay. The patient's plasma was mixed with a normal reference plasma (normal control, Siemens). Normal control plasma and patient's plasma dilutions were made in imidazole buffer; FVIII deficient plasma of Siemens was used. After a 2 hours incubation at 37°C, residual FVIII was measured. One Bethesda Unit (BU) was defined as the amount of antibody inactivating one-half of the factor VIII in the mixture. The positivity threshold for inhibitors was set at 0.6 BU, with a hemophiliac classified as a high responder when the inhibitor titer was greater or equal than 5 BU.

The molecular study strategy used for the F8 gene associated with hemophilia A is dependent on the severity of the hemophilia. The initial approach in severe hemophilia A patients was to test for the presence of intron 22 microinversion using Long Range Polymerase Chain Reaction (LR PCR). If negative, the microinversion of intron 1 was tested by triplex PCR. In the absence of these two micro-inversions, all 26 exons of the F8 gene and their flanking regions were sequenced, followed if necessary by sequencing of the promoter and 3'UTR region. In cases of moderate or minor hemophilia, the search for genetic mutations is carried out directly by sequencing the 26 exons and their flanking regions. In case of negativity, sequencing of the promoter and the 3'UTR region was performed. Interpretation and nomenclature of the anomalies identified were based on international databases of hemophilia genetic anomalies.

### 3. RESULTS AND DISCUSSION

Of the 97 PwHs A monitored in HTC in Benin, 57 had been treated with infused factor VIII. The distribution of these patients according to the severity of hemophilia A revealed that 48 patients were severe form, eight were moderate, and one patient had mild hemophilia. Among the 57 treated patients, 21 had developed anti-factor VIII antibodies, resulting in a prevalence of 36.8% of inhibitors among treated hemophilia A patients and 43.75% among severe hemophilia A patients. None of the moderate or mild hemophilia A patients carried anti-factor VIII inhibitors during this study, as shown in Table 1.


PwHs A with inhibitors had a median age of 11 years, ranging from 1 to 66 years. Their distribution is depicted in Fig. 1. They predominantly resided in the departments of Atlantique (8 patients), Littoral (5 patients), and Borgou (3 patients). The departments of Zou (2 patients), Collines (1 patient), and Ouémé (1

patient) had the lowest representation. Regarding ethnicity, 11 patients were Fon, followed by Adja (5 cases), and Yoruba (4 cases). Only one Dendi individual developed anti-factor VIII antibodies.

The mean age at the onset of initial bleeding in these PwHs was 3 years 8 months with the range of 3 months and 10 years. However, the diagnosis of hemophilia was established at a mean age of 5 years and 8 months, ranging from 3 months to 21 years. Discovery circumstances were mainly post-traumatic cutaneous-mucosal bleeding (8 cases), post-circumcision bleeding (6 cases), and recurrent hemarthrosis (6 cases). Two patients were identified through family screening. The mean number of annual bleeding rates among these 21 PwH was 34, ranging from 10 to 96 per year. Among these bleeding episodes, four patients had a history of intracranial hemorrhage, and two had a history of psoas hematoma with blood loss and anemia decompensation. All 21 patients had a history of hemarthrosis, and 19 had hemophilic arthropathy at the time of this study. Regarding family history of hemophilia, 10 of the 21 hemophilia A patients who developed inhibitors reported a family history of hemophilia, while this history was not found in four patients. Additionally, seven patients were unaware of the presence or absence of hemophilia in their families. None of the 21 patients were aware of a family history of anti-factor VIII inhibitors. Their distribution according to the discovery circumstances of the inhibitors revealed 12 cases of therapeutic inefficacy, 4 cases of intracranial hemorrhage, and 5 cases of inhibitor detection following the management of post-traumatic bleeding events (road traffic accidents, psoas hematoma, circumcision) during this study. Additionally, all patients were on-demand treatment before inhibitor development. The mean number of days exposure was 22 per PwHs, ranging from 5 to 59 EDs. Two patients out of the 21 had more than 50 EDs at the time of inhibitor discovery during this study.

**Table 1. Frequency of beninese PwHs A with inhibitors**

	Number of PwHs A	Number of PwHs A treated with infused FVIII	Number of patients with inhibitors	Frequency of occurrence of inhibitors
Number of PwHs A	97	57	21	36,8%
Number of severe PwHs A	65	48	21	43,75%
Number of moderate PwHs A	25	08	00	00%
Number of mild PwHs A	06	01	00	00%



**Fig. 1. Distribution of age of PwHs A with inhibitor**

Inhibitor screening was conducted by the absence of mixing test correction with a circulating anticoagulant index (Rosner index) greater than 15 in the 21 PwHs A. Performing the modified Bethesda assay revealed 11 patients with an anti-factor VIII inhibitor titer > 5 BU, while the other 10 had titers ranging between 0.7 and 4.5 BU.

Among the 21 patients, mutations could not be identified in 3 patients due to the absence of DNA amplification during the search for intron 22 inversion. Of the remaining 18 patients, seven carried intron 22 inversion, seven had nonsense mutations, and three patients had a deletion in the F8 gene. Among these three, one had an intron 26 + 3'UTR deletion, and two had a single nucleotide deletion. Finally, one out of the 21 PwHs carried a missense mutation and developed anti-factor VIII inhibitors (Table 2).

**Table 2. Frequency of types of mutations in PwHs A with inhibitors**

Type of mutations	Effective	Frequency
Intron 22 inversion	7/18	38,9%
Nonsense mutation	7/18	38,9%
Deletion	3/18	16,7%
Missense mutation	1/18	5,5%

In terms of therapy, immune tolerance induction was not achieved in any of the 21 patients, but 10, including all those who developed severe hemorrhagic events, were placed on prophylactic emicizumab treatment, and the other 11 were on-demand activated prothrombin complex concentrate treatment.

#### 4. DISCUSSION

In our study, we investigated inhibitors among beninese PwHs A treated with infused factor VIII and found a frequency of 36.8%. This frequency is higher than that generally observed in the caucasian population, which was 7% in France [6], and ranged from 3.6% [7] to 27% [8] in the literature. For studies with sample sizes of over 500 patients with hemophilia A, reported prevalences of anti-factor VIII inhibitors were typically lower, ranging from 5% to 7% [3], except for two studies that included over 1000 hemophilia A patients, where reported inhibitor prevalences exceeded 10% [9,10]. When studies involve smaller hemophilia cohorts, reported inhibitor prevalences appear higher. For instance, in Turkey, a study of 58 children with hemophilia A by Ören et al. reported 27% prevalence of inhibitors [8], while Aronis found a prevalence of 26.8% in Greece [11]. Regarding studies conducted in sub-Saharan Africa, sample sizes ranged from 22 in Senegal to 54 in Ivory Coast, with respective prevalence rates of 20% [12] and 12% [13]. These data reveal a higher inhibitor frequency in our study population compared to studies conducted in the sub-region. This difference could be explained either by the presence of transient inhibitors in some of the patients with hemophilia A included in our study, or by the fact that almost all PwHs treated in Benin were on-demand treatment, which is another risk factor for developing anti-factor VIII inhibitors [14,15]. Additionally, the types of therapeutic factors and their origins (plasma-derived or recombinant) used vary within the same PwH from one bleeding episode to

another, which constitutes an additional risk factor [15]. Furthermore, none of the patients had undergone immune tolerance induction since the use of factor VIII in Benin. Nevertheless, according to many authors, the frequency of inhibitors is higher in black patients with hemophilia A than in the caucasian population because F8 gene haplotypes differ between races [16-18]. Indeed, haplotype H1 is more prevalent in the caucasian population (60%) and H2 in Africans (74%), while haplotypes H3 and H5 are exclusively found in africans. Therapeutic factor VIII products have been produced using H1 or H2 haplotypes [16], which enhances the immunogenicity of the therapeutic FVIII protein.

During our study, a high number of annual bleeding episodes were recorded among the 21 patients, six of whom developed severe hemorrhagic manifestations, and 19 developed hemophilic arthropathy. This confirms the significant morbidity of hemophilia in patients who develop inhibitors and the impairment of their quality of life [19-21]. Additionally, as this study is the first conducted in our country, all 21 PwHs with inhibitors were unaware of whether they had a family history of anti-factor VIII inhibitors. The circumstances of inhibitor discovery among these PwHs were mainly therapeutic inefficacy during the treatment of bleeding episodes or during systematic screening during the study. Indeed, very few hemophiliacs come for routine consultation for their follow-up in Benin either due to lack of financial means to pay consultation fees or because they reside far from the hemophilia treatment center (HTC) in Cotonou, where specific tests like inhibitor screening are available. Hence, there is a need to establish HTC in each of the 12 departments of Benin and to train laboratory personnel.

Given that inhibitor development is a multifactorial process, with the best-characterized risk factor being the type of F8 gene mutation, genetic mutations were identified in 18 out of the 21 patients who developed anti-factor VIII inhibitors, with seven carrying intron 22 inversion (38.9%), seven carrying nonsense mutations (38.9%), and three patients having a deletion (16.7%). Indeed, according to the literature, patients with significant F8 rearrangements such as inversions, nonsense mutations, and large deletions have a high risk of developing FVIII inhibitors [19]. The same holds true for single nucleotide deletions, as found in two patients in our study, which are also

considered high-risk mutations as they lead to a change in the reading frame and thus a stop codon [22]. Moreover, a case of missense mutation was associated with a severe phenotype of hemophilia A and developed inhibitors. While many authors associate missense mutations with a low risk of inhibitor occurrence [19], Fodil et al. reported a frequency of 13.51% of severe hemophilia A patients with missense mutations who developed inhibitors in their study [23]. According to their study, the risk of developing anti-FVIII inhibitors increases when the substitution results in an amino acid class change. Indeed, in the missense mutation found in patient HA 56 during our study, arginine was replaced by histidine at position 2169. According to the amino acid distribution, arginine belongs to class 4 (basic), while histidine is polar, neutral, and belongs to class 2 [23]. Therefore, it is necessary to continue this study on a larger population to better understand these different mechanisms in the Beninese population.

## 5. CONCLUSION

Despite being a cross-sectional study with a limited sample size, this study provides valuable insights into the population of Beninese patients with hemophilia A with inhibitors. It has highlighted the absence of systematic and screening for anti-factor VIII inhibitors during the first 50 EDs and of immune tolerance induction. Moreover, nearly all patients who developed inhibitors carried high-risk genetic mutations such as intron 22 inversion, nonsense mutations, and deletions. In addition to this genetic risk factor, other environmental factors such as on-demand treatment and changing therapeutic factor VIII types with each bleeding episode contribute to inhibitor development. Finally, the management of these patients has been facilitated by the introduction of new non-substitutive therapies and bypassing agents.

## CONSENT AND ETHICAL APPROVAL

This study received approval from the Institutional Committee of Ethics and Research at the University of Parakou (Benin) (Authorization 0464/CLERB-UP/P/SP/R/SA). Prior to the study commencement, participants were provided with detailed information through a newsletter, which included the study's objectives, benefits, and associated risks, in order to obtain informed consent. The confidentiality of research results was maintained by utilizing a unique code for each patient.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Kessler C, Oldenburg J, Ettingshausen CE, Tiede A, Khair K, Négrier C KR. Spotlight on the human factor: Building a foundation for the future of haemophilia A management: Report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014. *Haemophilia* 2015;21:1–12.
2. Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW and al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. *J Thromb Haemost.* 2004;2(7):1047-54. DOI: 10.1046/j
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. *Haemophilia*. 2003;9(4):418-35. DOI: 10.1046/j.1365-2516.2003.00780.x PMID: 12828678
4. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. *Br J Haematol.* 2006;133(6):591-605. DOI: 10.1111/j.1365-2141.2006.06087.x PMID: 16704433.
5. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. *Haemophilia*. 2006;12(6):15-22. DOI: 10.1111/j.1365-2516.2006.01361.x PMID: 17123389.
6. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. *Thromb Haemost.* 1992;67(6):600-2. PMID: 1509398.
7. Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: A single-centre experience over 34 years, 1964-97. *Br J Haematol.* 1999;104(4):909-14. DOI: 10.1046/j.1365-2141.1999.01268.x PMID: 10192458.
8. Oren H, Yaprak I, Irken G. Factor VIII inhibitors in patients with hemophilia A. *Acta Haematol.* 1999;102(1):42-6. DOI: 10.1159/000040966 PMID: 10473887.
9. Rieger A, Roisenberg I. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil. *Thromb Haemost.* 1999;81(3):475-6. PMID: 10102489.
10. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. *Prog Clin Biol Res.* 1984;150:19-29. PMID: 6431427.
11. Aronis S, Platokouki H, Kapsimali Z, Adamtziki E, Kolokithas A, Mitsika A. Prevalence of inhibitor formation in a cohort of haemophilic children exposed to several products of various purities. *Haemophilia*. 1995;1(4):236-42. DOI: 10.1111/j.1365-2516.1995.tb00082.x PMID: 27214630.
12. Seck M, Costa C, Faye BF, Sy Bah D, Touré SA, Dieng N and al. Molecular diagnosis of haemophilia A in patients from Senegal. *Haemophilia*. 2017;23(3):e225-e227. DOI: 10.1111/hae.13207 EPUB 2017 Mar 17. PMID: 28306216.
13. Lambert C, Lannoy N, Meité N, Sanogo I, Eeckhoudt S, Hermans C. Inhibitor epidemiology and genetic-related risk factors in people with haemophilia from Côte d'Ivoire. *Haemophilia*. 2020;26(1):79-85. DOI: 10.1111/hae.13902 EPUB 2019 Dec 12. PMID: 31829478.
14. Iorio A, Halimeh S, Holzhauser S, Goldenberg N, Marchesini E, Marcucci M and al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: A systematic review. *J Thromb Haemost.* 2010;8(6):1256-65. DOI: 10.1111/j.1538-7836.2010.03823.x Epub 2010 Mar 17. PMID: 20345722.
15. Lillicrap D, Fijnvandraat K, Santagostino E. Inhibitors - genetic and environmental factors. *Haemophilia*. 2014;20 Suppl 4:87-93. DOI: 10.1111/hae.12412. PMID: 24762282.
16. Lochan A, Macaulay S, Chen WC, Mahlangu JN, Krause A. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. *Haemophilia*. 2014;20(5):687-92. DOI: 10.1111/hae.12436. Epub 2014 Jun 21. PMID: 24953131.

17. Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC and al. Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. *Blood*. 2015;126(7): 895-904.  
DOI: 10.1182/blood-2014-09-599365  
EPUB 2015 Jan 23. PMID: 25617427; PMCID: PMC4536543.
18. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C and al. Inhibitors of factor VIII in black patients with hemophilia. *N Engl J Med*. 2009;360(16): 1618-27.  
DOI: 10.1056/NEJMoa075760  
Erratum in: *N Engl J Med*. 2009 Jul 30;361(5):544.  
PMID: 19369668; PMCID: PMC2761028.
19. Coppola A, Santoro C, Tagliaferri A, Franchini M, Di Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. *Haemophilia*. 2010;16 Suppl 1:13-9.  
DOI: 10.1111/j.1365-2516.2009.02175.x  
PMID: 20059564.
20. Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia a. *Thromb Res*. 2018;168:20-27.  
DOI: 10.1016/j.thromres.2018.05.027  
Epub 2018 May 25. PMID: 29879570.
21. Franchini M, Coppola A, Rocino A, Santagostino E, Tagliaferri A, Zanon E and al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: A 2013 update. *Semin Thromb Hemost*. 2013;39(7):752-66.  
DOI: 10.1055/s-0033-1356715  
Epub 2013 Sep 10. PMID: 24022806.
22. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. *Haemophilia*. 2006;12(3):52-60.  
DOI: 10.1111/j.1365-2516.2006.01261.x  
PMID: 16683997.
23. Fodil M, Zemani F. In Silico Study of Correlation between Missense Variations of F8 Gene and Inhibitor Formation in Severe Hemophilia A. *Turk J Haematol*. 2020;37(2):77-83.  
DOI: 10.4274/tjh.galenos.2019.2019.0094  
EPUB 2019 Dec 26. PMID: 31876401; PMCID: PMC7236410.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/113484>